BioXcel Therapeutics (BTAI) Interest Coverage Ratio Growth (1y) (2020 - 2026)
Powered by 
Analysis
BioXcel Therapeutics (BTAI) Interest Coverage Ratio Growth (1y) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 36.43% |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | -532.04% |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | -60.78% |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | 176.09% |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 1,170.12% |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | - |
| 10 | BioXcel Therapeutics | 2.19 Mn | 2.19 Mn | 160,000.00 | 36.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 36.23% |
| Mar 31, 2026 | 3.72% |
| Dec 31, 2025 | 10.12% |
| Sep 30, 2025 | 19.37% |
| Jun 30, 2025 | 19.68% |
| Mar 31, 2025 | 62.25% |
| Dec 31, 2024 | 55.02% |
| Sep 30, 2024 | 72.83% |
| Jun 30, 2024 | 70.93% |
| Mar 31, 2024 | 55.95% |
| Dec 31, 2023 | 68.06% |
| Sep 30, 2023 | -40.93% |
| Jun 30, 2023 | 29.71% |
| Mar 31, 2023 | 99.66% |
| Dec 31, 2022 | 99.58% |
| Sep 30, 2022 | 99.57% |
| Jun 30, 2022 | 98.67% |
| Mar 31, 2022 | -19.34% |
| Dec 31, 2021 | 17.43% |
| Sep 30, 2021 | 50.79% |